Singapore: Australian biopharmaceutical giant CSL has marked sales of $5 billion, achieving a net profit after tax (NPAT) of $1,216 million for the 12 months ending June 30, 2013.

CSL invested $427 million on R&D and accelerated sales growth in immunoglobulins, albumin and specialty products.

CSL CEO, Mr Paul Perreault said, "This is an excellent
result and reflects the combined effort of many people across the company, in particular our immediate past CEO, Dr Brian McNamee."

"The company's core products of immunoglobulin and albumin have performed very well and we have strengthened our margins through a change in sales mix and a relentless pursuit of efficiency," he added.

"Our suite of specialty products grew strongly, supported by the
registration in the US of Kcentra, a product used in the urgent reversal of
anticoagulant warfarin in patients with acute major bleeding," Mr Perreault
said.

Immunoglobulin product marked sales of $2,081 million, growing at 9
percent in constant currency terms. Demand for subcutaneous immunoglobulin (SCIG), lead by Hizentra, was particularly strong in both the US and Europe, growing 27 percent in constant currency terms, when compared to the prior comparable period.